Advancells, an India-based research oriented company recently announced successful reversal of Multiple Sclerosis using Adult Stem Cells and Regenerative medicine in the pilot patient of a planned clinical trial.

An Auckland, New Zealand resident has become the first patient to be recruited under a pilot study to ascertain the efficacy of Autologous Adult Stem Cells in reversing Multiple Sclerosis (MS). MS is a disease of the nerves where the insulating covers of the nerve cells in the brain and nerves are damaged, thus effecting the communication between those nerves and the brain. This results in disabling the patient in their muscle movement, vision, coordination and sensation.

The Patient from New Zealand was first diagnosed with MS in 2010 and has had multiple relapses of the disease in the past 7 years. His symptoms had been progressing at a fast pace and he had almost lost his power to walk. The patient then approached the Institute and was accepted as a trial patient for Advancells unique Adult Stem Cell therapy program and the procedure was carried out in New Delhi in June 2017.

Advancells gets approached by a lot of patients from around the world who wish to be a part of their program but they cannot take commercials therapies just yet. Patient selection is a key criterion for them and the approached patient suited the criterions perfectly. He is young, still at a moderate level of the disease and in a very positive frame of mind. Patients at this stage are best suited for this kind of treatment and thus he was accepted as a pilot case.

To perform the therapy, bone marrow of the patient was aspirated and adult stem cells were separated from them. These unmanipulated cells were then reinjected back in the patient at specific points and the patient was put under physiotherapy and dietary routine.
Straight after the treatment the patient saw major improvements wherein he could walk a lot better, could climb stairs (which he was unable to do after 2012) and even go on the treadmill.

As per Advancells It will take approximately 3 months for them to review changes in the MRI of the patient but the drastic changes in symptoms clearly are an indication of the fact that the treatment is working and could become a hope for millions of patients across the world, who are suffering from this disease.

The company believes this is a good start to a lengthy research phase and it seems that they are on the right track and hopefully they will be able to make a significant contribution in eradicating not only MS but a host of untreatable diseases existing today and in the future.

Want to write for InnoHEALTH? send us your article at  magazine@innovatiocuris.com

Read all the issues of InnoHEALTH magazine:
InnoHEALTH Volume 1 Issue 1 (July to September 2016) – https://goo.gl/iWAwN2 
InnoHEALTH Volume 1 Issue 2 (October to December 2016) – https://goo.gl/4GGMJz 
InnoHEALTH Volume 2 Issue 1 (January to March 2017) – https://goo.gl/DEyKnw 
InnoHEALTH Volume 2 Issue 2 (April to June 2017) – https://goo.gl/Nv3eev
InnoHEALTH Volume 2 Issue 3 (July to September 2017) – https://goo.gl/MCVjd6
InnoHEALTH Volume 2 Issue 4 (October to December 2017) – http://amzn.to/2B2UMLw

Connect with InnovatioCuris on:
Facebook: https://www.facebook.com/innovatiocuris
Twitter: https://twitter.com/innovatiocuris
LinkedIn: https://www.linkedin.com/groups/7043791
Stay updated about IC, visit: www.innovatiocuris.com